BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26201283)

  • 21. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
    Bo MD; Del Principe MI; Pozzo F; Ragusa D; Bulian P; Rossi D; Capelli G; Rossi FM; Niscola P; Buccisano F; Bomben R; Zucchetto A; Maurillo L; de Fabritiis P; Amadori S; Gaidano G; Gattei V; Del Poeta G
    Ann Hematol; 2014 Oct; 93(10):1765-74. PubMed ID: 24923451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
    Flowers CR; Brown JR; Rosenthal H; Stock W; Katzen HI; Cohen JB; Sinha R; Lakhanpal S; Leis JF; Waller EK; Jaye DL
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):694-8. PubMed ID: 26385641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.
    Doubek M; Brychtova Y; Panovska A; Sebejova L; Stehlikova O; Chovancova J; Malcikova J; Smardova J; Plevova K; Volfova P; Trbusek M; Mraz M; Bakesova D; Trizuljak J; Hadrabova M; Obrtlikova P; Karban J; Smolej L; Oltova A; Jelinkova E; Pospisilova S; Mayer J
    Am J Hematol; 2015 May; 90(5):417-21. PubMed ID: 25645263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
    Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
    Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
    Rai KR; Freter CE; Mercier RJ; Cooper MR; Mitchell BS; Stadtmauer EA; Santábarbara P; Wacker B; Brettman L
    J Clin Oncol; 2002 Sep; 20(18):3891-7. PubMed ID: 12228210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
    Cortelezzi A; Pasquini MC; Gardellini A; Gianelli U; Bossi A; Reda G; Sarina B; Musto P; Barcellini W; Neri A; Deliliers GL
    Leukemia; 2009 Nov; 23(11):2027-33. PubMed ID: 19641526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
    J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
    Hoyle M; Crathorne L; Garside R; Hyde C
    Health Technol Assess; 2011 May; 15 Suppl 1():61-7. PubMed ID: 21609654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
    Jones JA; Ruppert AS; Zhao W; Lin TS; Rai K; Peterson B; Larson RA; Marcucci G; Heerema NA; Byrd JC
    Leuk Lymphoma; 2013 Dec; 54(12):2654-9. PubMed ID: 23547837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
    Zent CS; Bowen DA; Conte MJ; LaPlant BR; Call TG
    Leuk Lymphoma; 2016 Jul; 57(7):1585-91. PubMed ID: 26699397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).
    Schweighofer CD; Ritgen M; Eichhorst BF; Busch R; Abenhardt W; Kneba M; Hallek M; Wendtner CM
    Br J Haematol; 2009 Jan; 144(1):95-8. PubMed ID: 19016732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.
    Al-Sawaf O; Fischer K; Herling CD; Ritgen M; Böttcher S; Bahlo J; Elter T; Stilgenbauer S; Eichhorst BF; Busch R; Elberskirch U; Abenhardt W; Kneba M; Hallek M; Wendtner CM
    Eur J Haematol; 2017 Mar; 98(3):254-262. PubMed ID: 27862308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
    Elter T; Borchmann P; Schulz H; Reiser M; Trelle S; Schnell R; Jensen M; Staib P; Schinköthe T; Stützer H; Rech J; Gramatzki M; Aulitzky W; Hasan I; Josting A; Hallek M; Engert A
    J Clin Oncol; 2005 Oct; 23(28):7024-31. PubMed ID: 16145065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
    Lozanski G; Heerema NA; Flinn IW; Smith L; Harbison J; Webb J; Moran M; Lucas M; Lin T; Hackbarth ML; Proffitt JH; Lucas D; Grever MR; Byrd JC
    Blood; 2004 May; 103(9):3278-81. PubMed ID: 14726385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
    Lanasa MC; Andritsos L; Brown JR; Gabrilove J; Caligaris-Cappio F; Ghia P; Larson RA; Kipps TJ; Leblond V; Milligan DW; Janssens A; Johnson AJ; Heerema NA; Bühler A; Stilgenbauer S; Devin J; Hallek M; Byrd JC; Grever MR
    Leuk Res; 2015 May; 39(5):495-500. PubMed ID: 25804339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.
    Montillo M; Tedeschi A; Petrizzi VB; Ricci F; Crugnola M; Spriano M; Spedini P; Ilariucci F; Uziel L; Attolico I; Vismara E; De Blasio A; Zaccaria A; Morra E
    Blood; 2011 Oct; 118(15):4079-85. PubMed ID: 21772050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
    Guièze R; Robbe P; Clifford R; de Guibert S; Pereira B; Timbs A; Dilhuydy MS; Cabes M; Ysebaert L; Burns A; Nguyen-Khac F; Davi F; Véronèse L; Combes P; Le Garff-Tavernier M; Leblond V; Merle-Béral H; Alsolami R; Hamblin A; Mason J; Pettitt A; Hillmen P; Taylor J; Knight SJ; Tournilhac O; Schuh A
    Blood; 2015 Oct; 126(18):2110-7. PubMed ID: 26316624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
    Zent CS; Taylor RP; Lindorfer MA; Beum PV; LaPlant B; Wu W; Call TG; Bowen DA; Conte MJ; Frederick LA; Link BK; Blackwell SE; Veeramani S; Baig NA; Viswanatha DS; Weiner GJ; Witzig TE
    Am J Hematol; 2014 Jul; 89(7):757-65. PubMed ID: 24723493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
    Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
    Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.
    Fiegl M; Falkner F; Steurer M; Zojer N; Hopfinger G; Haslbauer F; Winder G; Voskova D; Andel J; Lang A; Brychtova Y; Mayer J; Greil R; Gastl G; ; ;
    Ann Hematol; 2011 Sep; 90(9):1083-91. PubMed ID: 21350830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.